US 11,807,905 B2
Growth differentiation factor 15 as biomarker for metformin
Sibylle Hess, Frankfurt am Main (DE); Thorsten Sadowski, Frankfurt am Main (DE); Hertzel Gerstein, Toronto (CA); Guillaume Pare, Puslinch (CA); and Gregory Steinberg, Ancaster (CA)
Assigned to Sanofi-Aventis Deutschland GmbH, Frankfurt am Main (DE); and McMaster University
Filed by Sanofi-Aventis Deutschland GmbH, Frankfurt am Main (DE); and McMaster University, Hamilton (CA)
Filed on Mar. 11, 2021, as Appl. No. 17/198,781.
Application 17/198,781 is a division of application No. 16/064,341, granted, now 10,975,434, previously published as PCT/EP2016/082163, filed on Dec. 21, 2016.
Claims priority of application No. 15202424 (EP), filed on Dec. 23, 2015.
Prior Publication US 2021/0254156 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/155 (2006.01); C12Q 1/6876 (2018.01)
CPC C12Q 1/6876 (2013.01) [A61K 31/155 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 12 Claims
 
1. A method for identifying a patient suffering from diabetes who will benefit from metformin treatment, said method comprising:
(a) administering metformin to a patient having diabetes;
(b) obtaining a sample from the patient;
(c) determining the level of GDF15 or a functional variant thereof in the sample; and
(d) comparing the level of GDF15 or functional variant thereof after the administration in step (a) to the level of GDF15 or functional variant in the patient before the administration or to a reference value, wherein an increased level of GDF15 or functional variant thereof after the administration in step (a) indicates that the patient responds to the metformin administration,
wherein the functional variant of GDF15 comprises a sequence having at least 80% sequence identity to SEQ ID NO: 1.